Richard Vile, Ph.D., and his research team develop experimental cancer therapies, all based on stimulating antitumor immune responses.
Dr. Vile's research combines in vivo and in vitro assays, but predominantly focuses in murine immune-competent models and syngeneic tumors. Although his team has a major interest in melanoma, they also have models of prostate cancer, glioma and brain metastases, and can be applied across tumor sites.